



Intern 1al Application No

			PCT/GB O	0/03343
A. CLASS	SIFICATION OF SUBJECT MATTER A61L27/34 A61L27/58			
	to International Patent Classification (IPC) or to both national	classification and IPC		
	S SEARCHED locumentation searched (classification system followed by cla	spification are to be		
IPC 7	A61L A61F	ssincation symbols)		
Documenta	tion conselved other than			
Documenta	ation searched other than minimum documentation to the exter	nt that such documents are included	ded in the fields s	earched
Electronic o	data base consulted during the international search (name of	data base and, where practical	search terms user	1)
EPO-In	ternal, WPI Data, PAJ	, constant	ocaron terms used	
C DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of	the relevant passages		
				Relevant to claim No.
Y	EP 0 633 032 A (SUMITOMO ELEC INDUSTRIES) 11 January 1995 (TRIC		1-15
	column 5, line 28; claims; exa	amples 1,2		
Υ	EP 0 183 365 A (COATS LTD J &	P)		1-15
	4 June 1986 (1986-06-04) cited in the application			1 13
	claims; examples			
Α	EP 0 742 020 A (NICEM LTD)			1-15
	13 November 1996 (1996-11-13) claims; examples			- 10
A	US 5 851 229 A (DEPREKER JENNI	EED FT ALL		
	22 December 1998 (1998-12-22)			1-15
	column 4, line 16 - line 46; c	laims		
İ		-/		
χ Furthe	r documents are listed in the continuation of box C.	X Patent family mer	nbers are listed in	annex.
	gories of cited documents :	*T* later document publishe	ad after the line	
A* document defining the general state of the art which is not considered to be of particular relevance		or priority date and no cited to understand the invention		
"E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or		"X" document of particular of cannot be considered	DOVELOR CORNAL P	a capsidared to
citation or other special reason (as specified)		"Y" document of particular	ep when the docu	ment is taken alone
 O* document referring to an oral disclosure, use, exhibition or other means 		document is combined ments, such combinati	to involve an inve	ntive step when the
P' document published prior to the international filing date but later than the priority date claimed		in the art. *& document member of th		
Jale of the act	ual completion of the international search	Date of mailing of the in		
4 0	December 2000	11/12/2000	0	
Name and mail	ling address of the ISA European Patent Office, P.B. 5818 Patentiaan 2	Authorized officer		
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo ni	ESPINOSA,	M	
Fax: (+31-70) 340-3016		ESTINUSA,	rı	

2

Interr nat Application No PCT/GB 00/03343

	PCT/GB 00/03343
ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
US 5 292 362 A (EATON ALEXANDER M ET AL) 8 March 1994 (1994-03-08) column 5, line 28; claims	1-15
US 4 902 290 A (WERNER HEINZ-HELMUT ET AL) 20 February 1990 (1990-02-20) cited in the application	·
GB 854 715 A (AKTIEBOLAGET PHARMACIA) 23 November 1960 (1960-11-23) cited in the application	
	·
	US 5 292 362 A (EATON ALEXANDER M ET AL) 8 March 1994 (1994-03-08) column 5, line 28; claims US 4 902 290 A (WERNER HEINZ-HELMUT ET AL) 20 February 1990 (1990-02-20) cited in the application GB 854 715 A (AKTIEBOLAGET PHARMACIA) 23 November 1960 (1960-11-23)



...ormation on patent family members

Interr nal Application No
PCT/GB 00/03343

Patent document cited in search report		Publication date		ntent family nember(s)	Publication date
EP 0633032	Α	11-01-1995	JP AU AU CA US	7067895 A 692445 B 6596094 A 2126608 A 5584877 A	14-03-1995 11-06-1998 05-01-1995 26-12-1994 17-12-1996
EP 0183365	A	04-06-1986	AT AU CA DE DE DK ES GR IE JP JP JP	83911 T 569645 B 5059385 A 1249490 A 3586941 T 551185 A 548138 D 8801577 A 852872 A 59421 B 1585374 C 2011258 B 61135651 A 4747848 A	15-01-1993 11-02-1988 05-06-1986 31-01-1989 11-02-1993 29-04-1993 31-05-1986 16-02-1988 16-04-1988 03-04-1986 23-02-1994 31-10-1990 13-03-1990 23-06-1986 31-05-1988
EP 0742020	Α	13-11-1996	JP CN US	8294530 A 1142974 A 5986168 A	12-11-1996 19-02-1997 16-11-1999
US 5851229	Α	22-12-1998	AU EP WO	4414097 A 0941131 A 9810804 A	02-04-1998 15-09-1999 19-03-1998
US 5292362	Α	08-03-1994	US AT AU CA DE DE EP ES JP WO	5209776 A 183656 T 8497991 A 2087957 A 69131556 D 69131556 T 0542880 A 2137930 T 6507376 T 9202238 A	11-05-1993 15-09-1999 02-03-1992 28-01-1992 30-09-1999 20-07-2000 26-05-1993 01-01-2000 25-08-1994 20-02-1992
US 4902290	A	20-02-1990	DE AT BR CA DE DK EP FI GR JP JP JP MX NO US	3608158 A 66126 T 8701135 A 1283505 A 3772070 A 127987 A 0237037 A 871065 A,B 3002895 T 1051263 B 1563185 C 62258666 A 165145 B 870809 A,B 4784659 A	25-01-1993 02-11-1989 12-06-1990 11-11-1987 29-10-1992
	 А		CH	413811 A	 31-05-1966

...ormation on patent family members

Intern nal Application No PCT/GB 00/03343

		1.0170	D 00/03343
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 854715 A		DE 1418013 A SE 169293 A	17-10-1968
			~~~~~~~


Form PCT/ISA/210 (patent family annex) (July 1992)





(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification	of Transmittal of International Search Report		
ACTION				
P24444A/SCR	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)		
International application No.		03/09/1999		
PCT/GB 00/03343	01/09/2000	03/07/1777		
Applicant				
SULZER VASCUTEK LIMITED e	t al.			
This International Search Report has bee according to Article 18. A copy is being tr	en prepared by this International Searching Au ansmitted to the International Bureau.	uthority and is transmitted to the applicant		
This International Search Report consists  It is also accompanied by	s of a total of3 sheets.  y a copy of each prior art document cited in the	nis report.		
Basis of the report				
a. With regard to the language, the	e international search was carried out on the to nless otherwise indicated under this item.			
the international search	was carried out on the basis of a translation o	of the international application furnished to this		
with regard to any nucleotide a	and/or amino acid sequence disclosed in the	e international application, the international search		
I was carried out on the pasis of t	the sequence listing: tional application in written form.			
contained in the internal	iternational application in computer readable t	form.		
	to this Authority in written form.			
	to this Authority in computer readble form.			
the statement that the s	subsequently furnished written sequence listin			
the statement that the i	nformation recorded in computer readable for	m is identical to the written sequence listing has been		
	(D. D.)			
	ound unsearchable (See Box I).			
3. Unity of invention is I	acking (see Box II).			
4. With regard to the <b>title</b> ,				
4. With regard to trie title,  The text is approved as	submitted by the applicant.			
the text has been esta	blished by this Authority to read as follows:			
1				
1				
5. With regard to the abstract,	a submitted by the applicant			
the text is approved a the text has been esta	s submitted by the applicant. ablished, according to Rule 38.2(b), by this Au n the date of mailing of this international searc	uthority as it appears in Box III. The applicant may, th report, submit comments to this Authority.		
	published with the abstract is Figure No.			
as suggested by the a		None of the figures.		
	t failed to suggest a figure.			
	etter characterizes the invention.			
L L				




### PATENT COOPERATION TREATY

### **PCT**

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	
P24444A/SCR	FOR FURTHER ACTION  See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/GB00/03343	International filing date (day/month/year)  01/09/2000  Priority date (day/month/year)  03/09/1999
International Patent Classification (IPC) or nat A61L27/34	
Applicant	
SULZER VASCUTEK LIMITED et al.	
This international preliminary examinand is transmitted to the applicant action.	nation report has been prepared by this International Preliminary Examining Authority ecording to Article 36.
2. This REPORT consists of a total of	4 sheets, including this cover sheet.
	by ANNEXES, i.e. sheets of the description, claims and/or drawings which have so for this report and/or sheets containing rectifications made before this Authority of the Administrative Instructions under the PCT).
These annexes consist of a total of 1	sheets.
3. This report contains indications relating	ng to the following items:
I ⊠ Basis of the report	
II Priority	
III 🔲 Non-establishment of opir	nion with regard to novelty, inventive step and industrial applicability
Lack of unity of invention	
V Reasoned statement under	er Article 35(2) with regard to novelty, inventive step or industrial applicability;
VI Certain documents cited	s suporting such statement
VII	rnational application
VIII	ne international application
Date of submission of the demand	Date of completion of this report
09/02/2001	02.08.2001
Name and mailing address of the international preliminary examining authority:	Authorized officer
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epi Fax: +49 89 2399 - 4465	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
. 4400	Telephone No. +49 89 2399 7809



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/03343

. B	sis of the report th regard to the elements of the international application (Replacement sheets which have been furnished to regard to the elements of the international application (Replacement sheets which have been furnished to the regard to the elements of the international application (Replacement sheets which have been furnished to report since they do not contain amendments (Rules 70.16 and 70.17)):
а	d are not annexed to this report since they be escription, pages:
1	19 as originally filed
•	laims, No.:
	as originally filed
	Vith regard to the <b>language</b> , all the elements marked above were available or furnished to this Authority in the anguage in which the international application was filed, unless otherwise indicated under this item.
	These elements were available or furnished to this Authority in the following language: , which is.
	the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
	the language of a translation furnished for the purposes of the international application (under Rule 48.3(b)).
	the language of a translation furnished for the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule the language of a translation furnished for the purposes of international preliminary examination (under Rule the language of a translation furnished for the purposes of international preliminary examination (under Rule 48.3(b)).
	the language of a translation furnished for the purposes of internation (
3.	55.2 and/or 55.3).  With regard to any <b>nucleotide and/or amino acid sequence</b> disclosed in the international application, the international application, the international preliminary examination was carried out on the basis of the sequence listing:
	the interpotional application in written form.
	the international application in computer readable terms
	and the device appearance by the Sauthority in written form.
	The statement that the subsequently furnished written sequence noting and the statement that the subsequently furnished
	the international application as filed rids between the international application as filed rids between the information recorded in computer readable form is identical to the written sequence
	listing has been turnished.
4	The amendments have resulted in the cancellation of:
	☐ the description, pages:
	The description Nos.:
	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/03343

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

- 6. Additional observations, if necessary:
- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N)

Yes:

Claims 1-15

No: Claims

Inventive step (IS)

Yes:

Claims 1-15

No: Claims


Industrial applicability (IA)

Yes:

Claims 1-15

No: Claims

2. Citations and explanations see separate sheet



# INTERNATIONAL PRELIMINARY International application No. PCT/GB00/03343 EXAMINATION REPORT - SEPARATE SHEET


#### Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The use of a polymer formed by cross-linking dextran molecules by formaldehyde and urea condensation as bioresorbable sealant composition for coating a prosthetic graft is not disclosed nor indicated by the relevant prior art (see International Search Report). The same applies for the methods of producing such coating or graft.

Claims 1-15 therefore appear novel and inventive in terms of Art. 33 (2) (3) PCT.

Claims 1-15 also fulfill the criteria for industrial applicability in terms of Art. 33 (4) PCT.



3

1	cross-linked dextran. Dextran is produced by a
2	fermentation process using Leuconostoc mesenteroides
3	bacteria growing on a sugar-based energy source, such
4	as sucrose. Partial hydrolysis of the fermentation
5	product yields dextrans of defined molecular weight.
6	These have been used widely as plasma substitutes with
7	a typical molecular weight of 40,000.
8	
9	Dextrans of this molecular weight are freely water-
10	soluble. To form a useful graft sealant, the dextrans
11	must be rendered insoluble. However, dextrans are not
12	easily cross-linked as they have limited reactive sites
13	to form intermolecular bonds. The available groups are
14	almost exclusively hydroxyl (OH) groups.
15	
16	British Patent No 854,715 describes the formation of a
17	dextran-based polymer by using epichlorohydrin.
18	However the epichlorohydrin-based approach forms very
19	stable cross-links so that the resultant polymer is
20	resistant to both enzymatic and hydrolytic attack and
21	does not biodegrade. Epichlorohydrin cross-linked
22	dextran is, therefore, unsuitable as a vascular graft
23	sealant as it is not bioresorbable and would not permit
24	tissue ingrowth within the timescale required. EP-B-
25	0,183,365 and US-A-4,747,848 both describe a gelatin-
26	based sealant in which the time-scale of reabsorption
27	is controllable.
28	
29	To overcome this problem, a novel dextran-based polymer
30	has been produced which is bioresorbable through
31	hydrolysis in the time scale of interest.
32	

